Bal Pharma Limited (NSE:BALPHARMA)
India · Delayed Price · Currency is INR 84.20
-5.49 (-6.12%)
Sep 18, 2025, 3:29 PM IST
Bal Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 2,946 | 3,031 | 3,392 | 3,042 | 2,812 | 2,505 | Upgrade |
| 2,946 | 3,031 | 3,392 | 3,042 | 2,812 | 2,505 | Upgrade | |
Revenue Growth (YoY) | -14.16% | -10.65% | 11.51% | 8.18% | 12.25% | 46.43% | Upgrade |
Cost of Revenue | 1,524 | 1,632 | 1,974 | 1,782 | 1,722 | 1,541 | Upgrade |
Gross Profit | 1,422 | 1,399 | 1,418 | 1,260 | 1,091 | 963.84 | Upgrade |
Selling, General & Admin | 622.94 | 634.09 | 615.25 | 560.62 | 478.19 | 425.59 | Upgrade |
Other Operating Expenses | 507.86 | 467.1 | 486.02 | 434.22 | 372.61 | 273.81 | Upgrade |
Operating Expenses | 1,229 | 1,199 | 1,202 | 1,086 | 941.21 | 794.62 | Upgrade |
Operating Income | 192.91 | 200.22 | 216.36 | 174.24 | 149.31 | 169.22 | Upgrade |
Interest Expense | -166.69 | -145.38 | -129.05 | -104.96 | -88.75 | -105.39 | Upgrade |
Interest & Investment Income | - | 10 | 5.6 | 2.31 | 3.7 | 3.14 | Upgrade |
Currency Exchange Gain (Loss) | - | 2.91 | -9.11 | -14.23 | 6.85 | -18.6 | Upgrade |
Other Non Operating Income (Expenses) | 21.07 | -16.51 | 5.84 | -11.2 | -1.71 | -6.81 | Upgrade |
EBT Excluding Unusual Items | 47.28 | 51.24 | 89.65 | 46.16 | 69.39 | 41.56 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | 0.83 | 0.39 | 12.34 | 0.21 | Upgrade |
Asset Writedown | - | - | - | - | - | -1.06 | Upgrade |
Pretax Income | 47.28 | 51.37 | 90.47 | 47.48 | 91.82 | 41.02 | Upgrade |
Income Tax Expense | -24.57 | -20.99 | 16.02 | 21.29 | 34.77 | -6.1 | Upgrade |
Earnings From Continuing Operations | 71.86 | 72.37 | 74.46 | 26.19 | 57.05 | 47.12 | Upgrade |
Minority Interest in Earnings | -0.29 | -0.21 | -0.54 | -0.48 | -0.93 | 0.3 | Upgrade |
Net Income | 71.57 | 72.15 | 73.92 | 25.72 | 56.12 | 47.42 | Upgrade |
Net Income to Common | 71.57 | 72.15 | 73.92 | 25.72 | 56.12 | 47.42 | Upgrade |
Net Income Growth | -5.42% | -2.39% | 187.44% | -54.17% | 18.33% | - | Upgrade |
Shares Outstanding (Basic) | 16 | 16 | 16 | 16 | 15 | 14 | Upgrade |
Shares Outstanding (Diluted) | 16 | 16 | 16 | 16 | 15 | 14 | Upgrade |
Shares Change (YoY) | 0.85% | 0.74% | 0.30% | 5.86% | 4.39% | 0.19% | Upgrade |
EPS (Basic) | 4.58 | 4.55 | 4.70 | 1.64 | 3.79 | 3.34 | Upgrade |
EPS (Diluted) | 4.58 | 4.55 | 4.70 | 1.64 | 3.79 | 3.34 | Upgrade |
EPS Growth | -6.22% | -3.11% | 186.59% | -56.71% | 13.36% | - | Upgrade |
Free Cash Flow | - | 15.28 | 118.26 | -161.83 | 183.26 | 189.71 | Upgrade |
Free Cash Flow Per Share | - | 0.96 | 7.51 | -10.31 | 12.36 | 13.36 | Upgrade |
Dividend Per Share | - | 1.200 | 1.200 | 1.000 | 1.000 | 1.000 | Upgrade |
Dividend Growth | - | - | 20.00% | - | - | - | Upgrade |
Gross Margin | 48.28% | 46.16% | 41.81% | 41.43% | 38.78% | 38.47% | Upgrade |
Operating Margin | 6.55% | 6.61% | 6.38% | 5.73% | 5.31% | 6.75% | Upgrade |
Profit Margin | 2.43% | 2.38% | 2.18% | 0.84% | 1.99% | 1.89% | Upgrade |
Free Cash Flow Margin | - | 0.50% | 3.49% | -5.32% | 6.52% | 7.57% | Upgrade |
EBITDA | 298.4 | 257.77 | 282.97 | 237.77 | 219.81 | 244.26 | Upgrade |
EBITDA Margin | 10.13% | 8.51% | 8.34% | 7.82% | 7.82% | 9.75% | Upgrade |
D&A For EBITDA | 105.49 | 57.55 | 66.62 | 63.54 | 70.51 | 75.03 | Upgrade |
EBIT | 192.91 | 200.22 | 216.36 | 174.24 | 149.31 | 169.22 | Upgrade |
EBIT Margin | 6.55% | 6.61% | 6.38% | 5.73% | 5.31% | 6.75% | Upgrade |
Effective Tax Rate | - | - | 17.70% | 44.84% | 37.87% | - | Upgrade |
Revenue as Reported | 2,967 | 3,053 | 3,421 | 3,052 | 2,864 | 2,517 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.